Publication at First Faculty of Medicine |
2009
Abstract
Age-related macular degeneration is leading cause of practical blindness in individuals over the age of 55 years in industrial countries. Anti-VEGF therapy targets angiogenesis and vascular permeability of choroidal neovascularisation secondary to Age-Related Macular Degeneration.
Ranibizumab (Lucentis), a recombinant, humanised, monoclonal antibody, inhibits all biologically active VEGF-A isoforms. In the article are presented results of randomised, controlled clinical trials with ranibizumab in the treatment of neovascular form of the Age-Related Macular Degeneration.